Catalyst Wire Dossier Catalyst Wire Dossier

APL-130277

APL-130277 · Sumitomo Pharma America, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for APL-130277, covering 2020-07-30 to 2023-11-22. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease [Phase 3]

See pricing